Current Report Filing (8-k)
January 11 2017 - 9:22AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 11, 2017
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33038
|
|
84-1475642
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston, Massachusetts
|
|
02129
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(617)
259-1970
(Registrants Telephone Number, including Area Code)
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the
Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR 240.14a-12).
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b)).
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c)).
|
Item 7.01
|
Regulation FD Disclosure
|
On January 11, 2017, ZIOPHARM Oncology, Inc., or the Company, will
present the attached presentation at the 35
th
Annual J.P. Morgan Healthcare Conference in San Francisco, California being held on January 9 13, 2017.
A copy of the above referenced presentation is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
This
information, including the information contained in the presentation furnished as Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by
reference into any of the Companys filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.
Item 9.01
|
Financial Statements and Exhibits
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Presentation of the Company dated January 11, 2017
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZIOPHARM Oncology, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Kevin G. Lafond
|
Date: January 11, 2017
|
|
|
|
|
|
Name: Kevin G. Lafond
|
|
|
|
|
|
|
Title: Sr. Vice President Finance, Chief
Accounting Officer and Treasurer
|
3
INDEX OF EXHIBITS
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Presentation of the Company dated January 11, 2017
|
4
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2024 to May 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about ZIOPHARM Oncology Inc (NASDAQ): 0 recent articles
More Ziopharm Oncology Inc News Articles